Avadel Pharmaceuticals plc (AVDL)
USD 6.6
(-2.94%)
USD 6.6
(-2.94%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 32.75 Million USD | -64.54% |
| 2022 | 92.39 Million USD | -35.88% |
| 2021 | 144.1 Million USD | 10.81% |
| 2020 | 130.05 Million USD | 4.87% |
| 2019 | 124 Million USD | 7.15% |
| 2018 | 115.73 Million USD | 74088.46% |
| 2017 | 156 Thousand USD | -71.48% |
| 2016 | 547 Thousand USD | -20.03% |
| 2015 | 684 Thousand USD | -99.1% |
| 2014 | 76.13 Million USD | 14.62% |
| 2013 | 66.42 Million USD | 98.53% |
| 2012 | 33.45 Million USD | 1624.59% |
| 2011 | 1.94 Million USD | 15.48% |
| 2010 | 1.68 Million USD | -44.19% |
| 2009 | 3.01 Million USD | 27.27% |
| 2008 | 2.36 Million USD | -3.23% |
| 2007 | 2.44 Million USD | -20.31% |
| 2006 | 3.06 Million USD | 3.51% |
| 2005 | 2.96 Million USD | 24.6% |
| 2004 | 2.37 Million USD | 22.83% |
| 2003 | 1.93 Million USD | 25.71% |
| 2002 | 1.54 Million USD | 68.31% |
| 2001 | 915 Thousand USD | -41.98% |
| 2000 | 1.57 Million USD | -24.9% |
| 1999 | 2.1 Million USD | -28.13% |
| 1998 | 2.92 Million USD | -2.6% |
| 1997 | 3 Million USD | 76.47% |
| 1996 | 1.7 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 34.33 Million USD | 4.8% |
| 2024 Q2 | 35.49 Million USD | 3.38% |
| 2023 Q4 | 32.75 Million USD | 1599.17% |
| 2023 Q1 | 93.77 Million USD | 1.5% |
| 2023 Q3 | 1.92 Million USD | 293.47% |
| 2023 FY | 32.75 Million USD | -64.54% |
| 2023 Q2 | 490 Thousand USD | -99.48% |
| 2022 Q4 | 92.39 Million USD | -16.73% |
| 2022 FY | 92.39 Million USD | -35.88% |
| 2022 Q1 | 118.02 Million USD | -18.1% |
| 2022 Q2 | 109.33 Million USD | -7.36% |
| 2022 Q3 | 110.96 Million USD | 1.48% |
| 2021 Q3 | 143.54 Million USD | 0.13% |
| 2021 Q4 | 144.1 Million USD | 0.39% |
| 2021 Q1 | 143.17 Million USD | 10.09% |
| 2021 FY | 144.1 Million USD | 10.81% |
| 2021 Q2 | 143.36 Million USD | 0.13% |
| 2020 FY | 130.05 Million USD | 4.87% |
| 2020 Q1 | 125.46 Million USD | 1.18% |
| 2020 Q2 | 126.96 Million USD | 1.2% |
| 2020 Q3 | 128.48 Million USD | 1.2% |
| 2020 Q4 | 130.05 Million USD | 1.22% |
| 2019 Q3 | 122.99 Million USD | 0.61% |
| 2019 Q1 | 121.06 Million USD | 4.61% |
| 2019 FY | 124 Million USD | 7.15% |
| 2019 Q4 | 124 Million USD | 0.82% |
| 2019 Q2 | 122.24 Million USD | 0.98% |
| 2018 Q2 | 113.03 Million USD | 1.18% |
| 2018 Q1 | 111.72 Million USD | 71517.95% |
| 2018 Q4 | 115.73 Million USD | 1.18% |
| 2018 Q3 | 114.38 Million USD | 1.19% |
| 2018 FY | 115.73 Million USD | 74088.46% |
| 2017 Q2 | 594 Thousand USD | 7.03% |
| 2017 Q4 | 156 Thousand USD | -74.59% |
| 2017 FY | 156 Thousand USD | -71.48% |
| 2017 Q1 | 555 Thousand USD | 1.46% |
| 2017 Q3 | 614 Thousand USD | 3.37% |
| 2016 Q3 | 734 Thousand USD | -6.85% |
| 2016 Q4 | 547 Thousand USD | -25.48% |
| 2016 Q2 | 788 Thousand USD | 10.99% |
| 2016 FY | 547 Thousand USD | -20.03% |
| 2016 Q1 | 710 Thousand USD | 3.8% |
| 2015 FY | 684 Thousand USD | -99.1% |
| 2015 Q1 | 78.55 Million USD | 3.18% |
| 2015 Q2 | 111.88 Million USD | 42.43% |
| 2015 Q4 | 684 Thousand USD | 0.0% |
| 2014 Q3 | 68.06 Million USD | -2.03% |
| 2014 Q4 | 76.13 Million USD | 11.86% |
| 2014 Q2 | 69.47 Million USD | 22.55% |
| 2014 FY | 76.13 Million USD | 14.62% |
| 2014 Q1 | 56.69 Million USD | -14.65% |
| 2013 Q1 | 50.92 Million USD | 52.22% |
| 2013 Q2 | 78.11 Million USD | 53.38% |
| 2013 Q3 | 65.52 Million USD | -16.12% |
| 2013 Q4 | 66.42 Million USD | 1.38% |
| 2013 FY | 66.42 Million USD | 98.53% |
| 2012 Q4 | 33.45 Million USD | 0.0% |
| 2012 Q2 | 48.04 Million USD | 0.09% |
| 2012 FY | 33.45 Million USD | 1624.59% |
| 2012 Q1 | 48 Million USD | 2374.38% |
| 2011 FY | 1.94 Million USD | 15.48% |
| 2011 Q1 | 1.89 Million USD | 12.98% |
| 2011 Q2 | 1.78 Million USD | -6.11% |
| 2011 Q3 | 1.97 Million USD | 10.55% |
| 2011 Q4 | 1.94 Million USD | -1.52% |
| 2010 Q1 | 2.8 Million USD | -6.71% |
| 2010 FY | 1.68 Million USD | -44.19% |
| 2010 Q4 | 1.68 Million USD | -7.89% |
| 2010 Q3 | 1.82 Million USD | -36.11% |
| 2010 Q2 | 2.85 Million USD | 1.67% |
| 2009 Q3 | 2.46 Million USD | 4.67% |
| 2009 Q4 | 3.01 Million USD | 22.11% |
| 2009 FY | 3.01 Million USD | 27.27% |
| 2009 Q1 | 2.25 Million USD | -4.69% |
| 2009 Q2 | 2.35 Million USD | 4.48% |
| 2008 Q3 | 2.43 Million USD | -9.51% |
| 2008 FY | 2.36 Million USD | -3.23% |
| 2008 Q1 | 2.57 Million USD | 5.48% |
| 2008 Q2 | 2.69 Million USD | 4.46% |
| 2008 Q4 | 2.36 Million USD | -2.95% |
| 2007 FY | 2.44 Million USD | -20.31% |
| 2007 Q4 | 2.44 Million USD | -21.52% |
| 2007 Q3 | 3.11 Million USD | 3.01% |
| 2007 Q2 | 3.02 Million USD | -0.46% |
| 2007 Q1 | 3.03 Million USD | -0.98% |
| 2006 Q3 | 2.65 Million USD | -4.05% |
| 2006 Q4 | 3.06 Million USD | 15.52% |
| 2006 Q2 | 2.76 Million USD | -2.64% |
| 2006 Q1 | 2.84 Million USD | -4.08% |
| 2006 FY | 3.06 Million USD | 3.51% |
| 2005 Q2 | 2.44 Million USD | -3.21% |
| 2005 FY | 2.96 Million USD | 24.6% |
| 2005 Q4 | 2.96 Million USD | -23.89% |
| 2005 Q3 | 3.89 Million USD | 59.29% |
| 2005 Q1 | 2.52 Million USD | 6.18% |
| 2004 Q4 | 2.37 Million USD | 19.32% |
| 2004 Q3 | 1.99 Million USD | 0.0% |
| 2004 FY | 2.37 Million USD | 22.83% |
| 2004 Q1 | 1.73 Million USD | -10.23% |
| 2004 Q2 | 1.99 Million USD | 14.67% |
| 2003 FY | 1.93 Million USD | 25.71% |
| 2003 Q4 | 1.93 Million USD | 21.99% |
| 2003 Q2 | 1.59 Million USD | 2.31% |
| 2003 Q1 | 1.56 Million USD | 1.36% |
| 2003 Q3 | 1.58 Million USD | -0.63% |
| 2002 Q3 | 1.37 Million USD | 0.0% |
| 2002 FY | 1.54 Million USD | 68.31% |
| 2002 Q4 | 1.54 Million USD | 12.16% |
| 2001 Q4 | 915 Thousand USD | 0.0% |
| 2001 FY | 915 Thousand USD | -41.98% |
| 2000 Q4 | 1.57 Million USD | 0.0% |
| 2000 FY | 1.57 Million USD | -24.9% |
| 1999 Q4 | 2.1 Million USD | 0.0% |
| 1999 FY | 2.1 Million USD | -28.13% |
| 1998 Q4 | 2.92 Million USD | 0.0% |
| 1998 Q1 | 2.9 Million USD | -3.33% |
| 1998 FY | 2.92 Million USD | -2.6% |
| 1997 FY | 3 Million USD | 76.47% |
| 1997 Q4 | 3 Million USD | 0.0% |
| 1996 Q4 | 1.7 Million USD | 0.0% |
| 1996 FY | 1.7 Million USD | 0.0% |
| 1996 Q1 | 1.8 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Cosmos Health Inc. | 3.03 Million USD | -979.286% |
| Safety Shot Inc | 304.9 Thousand USD | -10644.259% |
| Bright Green Corporation | 201.78 Thousand USD | -16135.262% |
| Embecta Corp. | 1.62 Billion USD | 97.984% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | 89.421% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | 64.03% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 93.314% |
| Dynavax Technologies Corporation | 252.41 Million USD | 87.022% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 93.468% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -145.835% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 93.624% |
| PainReform Ltd. | 30 Thousand USD | -109099.997% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -5977.527% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -5977.527% |
| SCYNEXIS, Inc. | 12.15 Million USD | -169.43% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -27869.161% |
| Journey Medical Corporation | 14.62 Million USD | -124.046% |
| Alpha Teknova, Inc. | 13.25 Million USD | -147.227% |
| Procaps Group, S.A. | 28.41 Million USD | -15.312% |
| Theratechnologies Inc. | 51.26 Million USD | 36.092% |
| Harrow Health, Inc. | 183.17 Million USD | 82.115% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -37555.171% |
| Biofrontera Inc. | 804 Thousand USD | -3974.627% |
| DURECT Corporation | 2.7 Million USD | -1112.435% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | 1.313% |
| Cronos Group Inc. | 1.55 Million USD | -2001.347% |
| OptiNose, Inc. | 611 Thousand USD | -5261.702% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 93.426% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | 4.183% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -7100.0% |
| Organogenesis Holdings Inc. | 60.74 Million USD | 46.07% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -156.255% |
| Radius Health, Inc. | 339.66 Million USD | 90.355% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -219.36% |
| Phibro Animal Health Corporation | 458.28 Million USD | 92.852% |
| Procaps Group S.A. | 28.41 Million USD | -15.312% |
| Alvotech | 1.02 Billion USD | 96.813% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -401.531% |
| Viatris Inc. | 16.18 Billion USD | 99.798% |
| Rockwell Medical, Inc. | 8.29 Million USD | -295.032% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -201.186% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -9650.261% |
| Tilray Brands, Inc. | 287.93 Million USD | 88.622% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | 72.816% |
| Shineco, Inc. | 10.01 Million USD | -227.033% |
| PetIQ, Inc. | 437.82 Million USD | 92.517% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -15500.0% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 87.317% |
| Alimera Sciences, Inc. | 64.48 Million USD | 49.201% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | 14.94% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -24150.678% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -377.735% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -4450.0% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -145603.607% |
| Hempacco Co., Inc. | 5.93 Million USD | -452.352% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 96.813% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | 41.725% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 94.683% |
| Currenc Group, Inc. | 2.5 Million USD | -1206.755% |
| Kamada Ltd. | 7.43 Million USD | -340.441% |
| Indivior PLC | 235.66 Million USD | 86.099% |
| Evoke Pharma, Inc. | 5 Million USD | -555.2% |
| Flora Growth Corp. | 942 Thousand USD | -3377.707% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -145603.607% |
| Evolus, Inc. | 120.35 Million USD | 72.781% |
| HUTCHMED (China) Limited | 48.18 Million USD | 32.018% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 94.44% |
| Akanda Corp. | 2.49 Million USD | -1211.893% |